Perennial Investment Advisors LLC Boosts Stock Position in Thermo Fisher Scientific Inc. $TMO

Perennial Investment Advisors LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 22.8% during the second quarter, HoldingsChannel reports. The firm owned 1,463 shares of the medical research company’s stock after acquiring an additional 272 shares during the period. Perennial Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $593,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the company. Flossbach Von Storch SE increased its stake in Thermo Fisher Scientific by 93.0% in the 2nd quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock worth $1,105,698,000 after acquiring an additional 1,314,182 shares during the last quarter. Nuveen LLC bought a new stake in Thermo Fisher Scientific during the first quarter worth about $532,360,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Thermo Fisher Scientific by 29.5% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,257,424 shares of the medical research company’s stock worth $915,295,000 after buying an additional 514,399 shares during the last quarter. EdgePoint Investment Group Inc. bought a new stake in shares of Thermo Fisher Scientific in the 1st quarter worth approximately $172,139,000. Finally, Lindsell Train Ltd lifted its stake in Thermo Fisher Scientific by 68.0% in the second quarter. Lindsell Train Ltd now owns 854,612 shares of the medical research company’s stock worth $346,511,000 after purchasing an additional 345,822 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on TMO shares. Raymond James Financial restated an “outperform” rating and issued a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. JPMorgan Chase & Co. boosted their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday, October 9th. Evercore ISI lifted their price target on Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Cowen restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Finally, Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. Nineteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $601.65.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $576.01 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The stock has a market cap of $216.41 billion, a price-to-earnings ratio of 33.28, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82. The stock has a 50 day moving average price of $531.35 and a 200-day moving average price of $470.43.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. The firm had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business’s revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the firm earned $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is currently 9.94%.

Thermo Fisher Scientific announced that its board has initiated a share repurchase plan on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 2.4% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Insider Activity

In related news, CAO Joseph R. Holmes sold 385 shares of the company’s stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $574.15, for a total value of $229,660.00. Following the transaction, the executive vice president owned 21,152 shares of the company’s stock, valued at $12,144,420.80. The trade was a 1.86% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 51,845 shares of company stock worth $28,956,952 over the last quarter. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.